Diphenhydramine hydrochloride (HCl)

Phase 2

Diphenhydramine hydrochloride (HCl) is one of 40 therapeutic programs targeting Lupus Nephritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lupus NephritisRecruiting

Lupus NephritisPhase 2

Recruiting

Competition

Competitive Landscape

54 competitors in Lupus Nephritis

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

25 2

Medrol

Pfizer

Approved

8 3

Rituxan

Roche

Approved

7 4

Cytoxan

BBaxter Healthcare Corporation

Approved

17 5

Farxiga

AstraZeneca

Approved

3 6

Myfortic

Novartis

Approved

2 7

Rocaltrol

Jazz Pharmaceuticals

Approved

2 8

Imuran

LLegacy Health System

Approved

10 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 10

Lupkynis

Aurinia Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Lupus Nephritis

NCT05039619

Clinical

Trials by Indication[1]

Lupus Nephritis1 trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

Recruiting· Roche logo

Roche·Phase 2·NCT05039619·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diphenhydramine hydrochloride (HCl). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Diphenhydramine hydrochloride (HCl). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Roche

Diphenhydramine hydrochloride (HCl)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Lupus Nephritis1 trial

References

Drug Info

Quick Facts

Related News